ADMA Biologics

ADMA Mid Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$9.19

+0.88% today

52W: $7.21 – $25.67

52W Low: $7.21 Position: 10.7% 52W High: $25.67

🔗 Compare Brokers

Key Metrics

P/E Ratio

15.32x

Price-to-Earnings

Forward P/E

6.66x

Forward Price/Earnings

P/S Ratio

4.29x

Price-to-Sales

EV/EBITDA

220.19x

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$2.2B

Market Capitalization

Revenue Growth

15.9%

YoY Revenue Growth

Profit Margin

28.8%

Net profit margin

ROE

35.56%

Return on Equity

Beta

0.82

Market sensitivity

Short Interest

13.32%

% of float sold short

Avg. Volume

4,986,977

Average daily volume

Valuation Analysis

Signal

Undervalued

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Buy

2 analysts

Avg. Price Target

$23.50

+155.71% upside

Target Range

$17.00 – $30.00

About the Company

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treat

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 640 Exchange: NGM